(Q44150673)

English

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

scientific article published in October 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

0 references

0 references

author name string

J B Marriott

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

I A Clarke

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

K Dredge

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

G Muller

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

D Stirling

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

A G Dalgleish

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

1 October 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Clinical and Experimental Immunology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

130

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

75-84

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Immunotherapeutic and antitumour potential of thalidomide analogues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Immune stimulation in scleroderma patients treated with thalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide as an emerging immunotherapeutic agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide: rationale for renewed use in immunological disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1906488

27 August 2018

Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of IL-12 production by thalidomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide analogs and PDE4 inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide on the comeback trail

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide--a revival story

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide therapy in refractory solid tumour patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12296856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1046/J.1365-2249.2002.01954.X

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44150673&oldid=2107176768"